B. Riley raised the firm’s price target on Longboard Pharmaceuticals to $45 from $36 and keeps a Buy rating on the shares post the Q2 report. The company announced regulatory alignment with the FDA for a broad-basket type of clinical program for treating developmental and epileptic encephalopathies with bexicaserin, a major win for shareholders, the analyst tells investors in a research note. The firm says LP659 is likely to serve as the next value driver for Longboard shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals price target raised to $50 from $45 at Citi
- Longboard Pharmaceuticals Reports Promising LP659 Study Results
- Longboard Pharmaceuticals reports Q2 EPS (56c), consensus (44c)
- Longboard Pharmaceuticals management to meet with Oppenheimer
- Don’t Miss Out! These 3 Stocks Are Set for Explosive Growth After Major Upgrades